In conversation with... Kanwal Raghav
from Listen to The Lancet Oncology Hosted by The Lancet
Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’.
Embed this episode
No transcript yet.
Similar podcasts
Frequently asked questions
How long is this episode of Listen to The Lancet Oncology?
This episode is 13 minutes long.
When was this Listen to The Lancet Oncology episode published?
This episode was published on August 28, 2024.
Can I download this Listen to The Lancet Oncology episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.